Effect of Supplementation of a Butyrate-Based Formula in Individuals with Liver Steatosis and Metabolic Syndrome: A Randomized Double-Blind Placebo-Controlled Clinical Trial

被引:3
|
作者
Fogacci, Federica [1 ]
Giovannini, Marina [1 ]
Di Micoli, Valentina [1 ]
Grandi, Elisa [1 ]
Borghi, Claudio [1 ]
Cicero, Arrigo Francesco Giuseppe [1 ]
机构
[1] Alma Mater Studiorum Univ Bologna, Med & Surg Sci Dept, Hypertens & Cardiovasc Risk Res Unit, I-40100 Bologna, Italy
关键词
butyrate; clinical trial; dietary supplement; NAFLD; postbiotics; DISEASE; MICROBIOME; KINASE; INDEX;
D O I
10.3390/nu16152454
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Postbiotics could exert different metabolic activities in animal models of non-alcoholic fatty liver disease (NAFLD) and in humans affected by metabolic syndrome. This is a randomized, double-blind, placebo-controlled, parallel-group clinical trial that enrolled a sample of 50 Caucasian healthy individuals with NAFLD, defined as liver steatosis, and metabolic syndrome. After a 4-week run-in, the enrolled individuals were randomized to take a food for special medical purposes with functional release, one tablet a day, containing calcium butyrate (500 mg/tablet), zinc gluconate (zinc 5 mg/tablet), and vitamin D3 (500 IU/tablet), or an identical placebo for 3 months. Liver and metabolic parameters were measured at baseline and at the end of the study. No subject experienced any adverse events during the trial. In both groups, a significant decrease in total cholesterol (TC) and triglycerides (TG) plasma levels was observed at the randomization visit vs. pre-run-in visit (p < 0.05). Regarding liver parameters, after treatment, the fatty liver index (FLI) improved significantly vs. baseline values (p < 0.05) and vs. placebo group (p < 0.05) in the active treatment group, and the hepatic steatosis index (HSI) improved significantly vs. baseline values (p < 0.05). Moreover, after active treatment, TC, TG, and gamma-glutamyl transferase (gGT) improved significantly vs. baseline values (p < 0.05), and TC and TG improved vs. placebo group (p < 0.05), as well. In the placebo group, liver parameters remained unchanged after treatment; only TG improved significantly vs. baseline values (p < 0.05). In our study, we observed that the butyrate-based formula improved FLI and plasma lipid patterns in individuals affected by liver steatosis and metabolic syndrome.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Quercetin supplementation in non-alcoholic fatty liver disease A randomized, double-blind, placebo-controlled clinical trial
    Hosseinikia, Mahboobe
    Oubari, Farhad
    Hosseinkia, Roghaye
    Tabeshfar, Zibaneh
    Salehi, Mohammad Gharib
    Mousavian, Zeinab
    Abbasi, Mehrnaz
    Samadi, Mehnoosh
    Pasdar, Yahya
    NUTRITION & FOOD SCIENCE, 2020, 50 (06): : 1279 - 1293
  • [42] The clinical effect of benesco™ on reflux symptoms: A double-blind randomized placebo-controlled trial
    Kuipers, Thijs
    Oude Nijhuis, Renske A. B.
    Schuitenmaker, Jeroen M.
    Bredenoord, Albert J.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2023, 35 (10):
  • [43] THE CLINICAL EFFECT OF BENESCOTM ON REFLUX SYMPTOMS: A DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL
    Kuipers, Thijs
    Berndien, Renske Anne
    Nijhuis, Oude
    Schuitenmaker, Jeroen M.
    Bredenoord, Arjan
    GASTROENTEROLOGY, 2023, 164 (06) : S586 - S586
  • [44] Effects of Vitamin D Supplementation in Patients with Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
    Jalili, Mahsa
    Vahedi, Homayoon
    Poustchi, Hossein
    Hekmatdoost, Azita
    INTERNATIONAL JOURNAL OF PREVENTIVE MEDICINE, 2019, 10
  • [45] A Randomized, Double-Blind, Placebo-Controlled Clinical Effect of a Xanthone-rich Dietary Supplement on Immune Function in Humans: A Randomized Double-Blind Placebo-Controlled Trial
    Tang, Yu-Ping
    Li, Peng-Gao
    Ji, Hongping
    Kou, Yan
    FASEB JOURNAL, 2008, 22
  • [46] Double-blind randomized placebo-controlled trial of sibutramine
    Bray, GA
    Ryan, DH
    Gordon, D
    Heidingsfelder, S
    Cerise, F
    Wilson, K
    OBESITY RESEARCH, 1996, 4 (03): : 263 - 270
  • [47] Effects of Butyrate Supplementation on Inflammation and Kidney Parameters in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
    Tougaard, Ninna H.
    Frimodt-Moller, Marie
    Salmenkari, Hanne
    Stougaard, Elisabeth B.
    Zawadzki, Andressa D.
    Mattila, Ismo M.
    Hansen, Tine W.
    Legido-Quigley, Cristina
    Horkko, Sohvi
    Forsblom, Carol
    Groop, Per-Henrik
    Lehto, Markku
    Rossing, Peter
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (13)
  • [48] The probiotic supplementation reduced inflammation in polycystic ovary syndrome: A randomized, double-blind, placebo-controlled trial
    Ghanei, Nila
    Rezaei, Nima
    Amiri, Ghorban Ali
    Zayeri, Farid
    Makki, Golbou
    Nasseri, Esmat
    JOURNAL OF FUNCTIONAL FOODS, 2018, 42 : 306 - 311
  • [49] Metabolic and hormonal effects of melatonin and/or magnesium supplementation in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial
    Mohammad Alizadeh
    Majid Karandish
    Mohammad Asghari Jafarabadi
    Lida Heidari
    Roshan Nikbakht
    Hossein Babaahmadi Rezaei
    Reihaneh Mousavi
    Nutrition & Metabolism, 18
  • [50] Metabolic and hormonal effects of melatonin and/or magnesium supplementation in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial
    Alizadeh, Mohammad
    Karandish, Majid
    Asghari Jafarabadi, Mohammad
    Heidari, Lida
    Nikbakht, Roshan
    Babaahmadi Rezaei, Hossein
    Mousavi, Reihaneh
    NUTRITION & METABOLISM, 2021, 18 (01)